After-Hours Movers 09/29: Nike, Micron Fall Post Earnings
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Amylyx Pharmaceuticals (AMLX) Sets List Price of $12,500 for 28-Day Supply of ALS Drug Relyvrio -- WSJ
September 30, 2022 8:49 AM EDTAmylyx Pharmaceuticals (NASDAQ: AMLX) Sets List Price of $12,500 for 28-Day Supply of ALS Drug Relyvrio -- WSJ
... MoreNike (NKE) PT Lowered to $114 at Cowen
September 30, 2022 8:28 AM EDTCowen analyst John Kernan lowered the price target on Nike (NYSE: NKE) to $114.00 (from $127.00) while maintaining a Outperform rating following earnings.
The analyst commented, "Nike is showing strength from a top-line perspective, and we think China could return to growth by Q2, but... More
Nike (NKE) PT Lowered to $115 at Jefferies
September 30, 2022 7:56 AM EDTJefferies analyst Randal Konik lowered the price target on Nike (NYSE: NKE) to $115.00 (from $130.00) while maintaining a Buy rating.
... MoreAmylyx Pharmaceuticals (AMLX) Confirms FDA Approval of RELYVRIO for the Treatment of ALS
September 30, 2022 7:05 AM EDTAmylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO (sodium phenylbutyrate and taurursodiol) for the treatment of adults with amyotrophic lateral sclerosis (ALS). RELYVRIO (previously known as AMX0035 in the U.S.) significantly slowed the loss of physical function in people living with ALS in a randomized, placebo-controlled clinical trial. RELYVRIO can be taken as a monotherapy or with existing approved treatments.
Todays FDA approval of RELYVRIO is an exciting milestone for the ALS community and is a major step... More
Micron Technology (MU) PT Lowered to $70 at BMO Capital
September 30, 2022 6:46 AM EDTBMO Capital analyst Ambrish Srivastava lowered the price target on Micron Technology (NASDAQ: MU) to $70.00 (from $80.00) while maintaining a Outperform rating following earnings.
The analyst commented, "We said heading into earnings that our thesis will be put to a severe test... More